 Corey Lyon
Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Physicians, Family | 2 | 2022 | 206 | 1.190 |
Why?
| | Osteoarthritis, Knee | 2 | 2018 | 240 | 0.940 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2024 | 2442 | 0.920 |
Why?
| | Hypertension | 4 | 2022 | 1243 | 0.890 |
Why?
| | Glucocorticoids | 3 | 2018 | 580 | 0.850 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2020 | 230 | 0.850 |
Why?
| | Medical Staff | 2 | 2022 | 16 | 0.820 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 2 | 2021 | 83 | 0.800 |
Why?
| | Papillomavirus Infections | 2 | 2020 | 297 | 0.800 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2024 | 89 | 0.780 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 984 | 0.760 |
Why?
| | Metformin | 2 | 2023 | 318 | 0.750 |
Why?
| | Sphygmomanometers | 1 | 2021 | 9 | 0.730 |
Why?
| | Insulin, Isophane | 1 | 2021 | 21 | 0.720 |
Why?
| | Automation | 1 | 2021 | 81 | 0.710 |
Why?
| | Humans | 55 | 2024 | 129626 | 0.700 |
Why?
| | Insulin Glargine | 1 | 2021 | 81 | 0.690 |
Why?
| | Early Detection of Cancer | 2 | 2022 | 370 | 0.690 |
Why?
| | Employment | 1 | 2022 | 167 | 0.680 |
Why?
| | Prediabetic State | 1 | 2023 | 244 | 0.680 |
Why?
| | Preventive Health Services | 1 | 2022 | 145 | 0.670 |
Why?
| | Blood Pressure Determination | 1 | 2021 | 148 | 0.670 |
Why?
| | Analgesia, Obstetrical | 1 | 2020 | 18 | 0.670 |
Why?
| | Analgesia, Epidural | 1 | 2020 | 23 | 0.670 |
Why?
| | Ganglion Cysts | 1 | 2020 | 10 | 0.660 |
Why?
| | Smoking Cessation | 1 | 2024 | 408 | 0.660 |
Why?
| | Aspirin | 2 | 2020 | 380 | 0.660 |
Why?
| | Post-Concussion Syndrome | 1 | 2023 | 167 | 0.650 |
Why?
| | Papillomaviridae | 1 | 2020 | 114 | 0.650 |
Why?
| | Anti-Bacterial Agents | 2 | 2021 | 1705 | 0.650 |
Why?
| | C-Reactive Protein | 2 | 2021 | 400 | 0.630 |
Why?
| | Wrist | 1 | 2020 | 54 | 0.630 |
Why?
| | Spironolactone | 1 | 2019 | 30 | 0.630 |
Why?
| | Diuretics | 1 | 2019 | 77 | 0.620 |
Why?
| | Probiotics | 1 | 2019 | 51 | 0.610 |
Why?
| | Ketorolac | 1 | 2019 | 20 | 0.610 |
Why?
| | Glucosamine | 1 | 2018 | 13 | 0.610 |
Why?
| | Memory | 1 | 2021 | 266 | 0.600 |
Why?
| | Erythromycin | 1 | 2018 | 24 | 0.600 |
Why?
| | Rh-Hr Blood-Group System | 1 | 2018 | 11 | 0.590 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 338 | 0.590 |
Why?
| | Glycemic Index | 1 | 2018 | 25 | 0.580 |
Why?
| | Viscosupplements | 1 | 2018 | 11 | 0.580 |
Why?
| | Acute Pain | 1 | 2019 | 45 | 0.580 |
Why?
| | Ureteral Calculi | 1 | 2018 | 13 | 0.580 |
Why?
| | Sweating | 1 | 2018 | 40 | 0.570 |
Why?
| | Musculoskeletal System | 1 | 2018 | 46 | 0.560 |
Why?
| | Antibiotic Prophylaxis | 1 | 2018 | 101 | 0.550 |
Why?
| | Testosterone | 1 | 2021 | 372 | 0.550 |
Why?
| | Hot Flashes | 1 | 2018 | 82 | 0.550 |
Why?
| | Patient Education as Topic | 2 | 2022 | 737 | 0.540 |
Why?
| | Obstetric Labor, Premature | 1 | 2017 | 35 | 0.540 |
Why?
| | Labor, Obstetric | 1 | 2017 | 58 | 0.520 |
Why?
| | Warfarin | 1 | 2017 | 147 | 0.520 |
Why?
| | Telemedicine | 2 | 2022 | 792 | 0.520 |
Why?
| | Hypoglycemia | 1 | 2021 | 427 | 0.520 |
Why?
| | Prenatal Diagnosis | 1 | 2018 | 194 | 0.520 |
Why?
| | Melatonin | 1 | 2017 | 125 | 0.520 |
Why?
| | Family Practice | 2 | 2018 | 455 | 0.520 |
Why?
| | Analgesics | 1 | 2018 | 191 | 0.510 |
Why?
| | Athletic Injuries | 1 | 2023 | 510 | 0.510 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2023 | 1365 | 0.500 |
Why?
| | Job Satisfaction | 1 | 2018 | 201 | 0.500 |
Why?
| | Practice Guidelines as Topic | 4 | 2020 | 1501 | 0.500 |
Why?
| | Carpal Tunnel Syndrome | 1 | 2016 | 27 | 0.500 |
Why?
| | Factor Xa Inhibitors | 1 | 2017 | 170 | 0.500 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2017 | 103 | 0.500 |
Why?
| | Hyaluronic Acid | 1 | 2018 | 216 | 0.490 |
Why?
| | Methylprednisolone | 1 | 2016 | 83 | 0.490 |
Why?
| | Migraine Disorders | 1 | 2017 | 101 | 0.490 |
Why?
| | Acute Coronary Syndrome | 1 | 2019 | 267 | 0.490 |
Why?
| | Brain Concussion | 1 | 2023 | 549 | 0.480 |
Why?
| | Menopause | 1 | 2018 | 297 | 0.470 |
Why?
| | Colorectal Neoplasms | 1 | 2022 | 749 | 0.450 |
Why?
| | Cough | 1 | 2015 | 116 | 0.440 |
Why?
| | Patient Care Team | 2 | 2018 | 600 | 0.430 |
Why?
| | Exercise Therapy | 1 | 2018 | 412 | 0.430 |
Why?
| | Mass Screening | 2 | 2022 | 1190 | 0.420 |
Why?
| | Antioxidants | 1 | 2017 | 558 | 0.420 |
Why?
| | Insulin | 1 | 2024 | 2326 | 0.420 |
Why?
| | Respiratory Tract Diseases | 1 | 2015 | 148 | 0.420 |
Why?
| | Adrenal Cortex Hormones | 1 | 2017 | 524 | 0.420 |
Why?
| | Myofascial Pain Syndromes | 2 | 2023 | 13 | 0.410 |
Why?
| | Acupuncture Therapy | 2 | 2023 | 21 | 0.410 |
Why?
| | Atrial Fibrillation | 1 | 2017 | 376 | 0.400 |
Why?
| | Anticoagulants | 1 | 2017 | 637 | 0.400 |
Why?
| | Behavior Therapy | 3 | 2023 | 241 | 0.390 |
Why?
| | Virus Diseases | 1 | 2015 | 210 | 0.390 |
Why?
| | Health Promotion | 1 | 2018 | 720 | 0.370 |
Why?
| | Low Back Pain | 2 | 2023 | 106 | 0.370 |
Why?
| | Cardiovascular Diseases | 2 | 2020 | 2006 | 0.350 |
Why?
| | Aged, 80 and over | 7 | 2021 | 7052 | 0.340 |
Why?
| | Pain Measurement | 4 | 2023 | 508 | 0.330 |
Why?
| | Aged | 10 | 2021 | 22061 | 0.300 |
Why?
| | Depression | 1 | 2017 | 1317 | 0.290 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2020 | 138 | 0.290 |
Why?
| | Female | 16 | 2023 | 68734 | 0.280 |
Why?
| | Papillomavirus Vaccines | 1 | 2010 | 232 | 0.280 |
Why?
| | Organizational Innovation | 2 | 2019 | 139 | 0.280 |
Why?
| | Pregnancy | 4 | 2022 | 6417 | 0.270 |
Why?
| | Abdomen, Acute | 1 | 2006 | 18 | 0.270 |
Why?
| | Azithromycin | 2 | 2018 | 93 | 0.260 |
Why?
| | Middle Aged | 11 | 2021 | 31136 | 0.260 |
Why?
| | Treatment Outcome | 7 | 2021 | 10219 | 0.250 |
Why?
| | Enuresis | 1 | 2005 | 3 | 0.250 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2005 | 11 | 0.250 |
Why?
| | Renal Agents | 1 | 2005 | 5 | 0.250 |
Why?
| | Adult | 9 | 2022 | 35599 | 0.220 |
Why?
| | Drug Administration Schedule | 2 | 2024 | 767 | 0.220 |
Why?
| | Hormone Replacement Therapy | 2 | 2023 | 93 | 0.210 |
Why?
| | Fibromyalgia | 1 | 2023 | 56 | 0.200 |
Why?
| | Vaping | 1 | 2024 | 54 | 0.200 |
Why?
| | Age Factors | 2 | 2022 | 3152 | 0.200 |
Why?
| | Naltrexone | 1 | 2023 | 87 | 0.200 |
Why?
| | Electronics | 1 | 2023 | 74 | 0.200 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2019 | 2011 | 0.190 |
Why?
| | Occult Blood | 1 | 2022 | 30 | 0.190 |
Why?
| | Hypoglycemic Agents | 2 | 2024 | 1221 | 0.190 |
Why?
| | Evidence-Based Medicine | 4 | 2019 | 712 | 0.190 |
Why?
| | United States | 5 | 2022 | 13871 | 0.180 |
Why?
| | Postmenopause | 1 | 2023 | 349 | 0.180 |
Why?
| | Lipid Regulating Agents | 1 | 2020 | 2 | 0.180 |
Why?
| | Life Style | 1 | 2023 | 461 | 0.180 |
Why?
| | Fish Oils | 1 | 2020 | 27 | 0.180 |
Why?
| | Time Factors | 2 | 2023 | 6555 | 0.180 |
Why?
| | Hypertriglyceridemia | 1 | 2020 | 39 | 0.170 |
Why?
| | Labor Stage, Second | 1 | 2020 | 3 | 0.170 |
Why?
| | Prenatal Care | 1 | 2022 | 277 | 0.170 |
Why?
| | Inpatients | 1 | 2024 | 475 | 0.160 |
Why?
| | Carcinoma, Basal Cell | 1 | 2020 | 74 | 0.160 |
Why?
| | Colonoscopy | 1 | 2022 | 238 | 0.160 |
Why?
| | Pain Management | 2 | 2023 | 324 | 0.160 |
Why?
| | Delivery, Obstetric | 1 | 2020 | 136 | 0.160 |
Why?
| | Ticlopidine | 1 | 2019 | 54 | 0.150 |
Why?
| | Systems Integration | 1 | 2018 | 37 | 0.150 |
Why?
| | Rho(D) Immune Globulin | 1 | 2018 | 3 | 0.150 |
Why?
| | Chondroitin Sulfates | 1 | 2018 | 35 | 0.150 |
Why?
| | Primary Health Care | 2 | 2019 | 1686 | 0.150 |
Why?
| | Male | 9 | 2021 | 63670 | 0.150 |
Why?
| | Clostridium Infections | 1 | 2019 | 64 | 0.150 |
Why?
| | Primary Prevention | 1 | 2020 | 190 | 0.150 |
Why?
| | Netherlands | 1 | 2018 | 77 | 0.150 |
Why?
| | Venlafaxine Hydrochloride | 1 | 2018 | 14 | 0.150 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 346 | 0.150 |
Why?
| | Proton Pump Inhibitors | 1 | 2019 | 100 | 0.150 |
Why?
| | Arthralgia | 1 | 2018 | 49 | 0.150 |
Why?
| | Citalopram | 1 | 2018 | 30 | 0.140 |
Why?
| | Injections, Intra-Articular | 1 | 2018 | 46 | 0.140 |
Why?
| | Visual Analog Scale | 1 | 2018 | 29 | 0.140 |
Why?
| | Pneumonia, Bacterial | 1 | 2019 | 115 | 0.140 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2018 | 43 | 0.140 |
Why?
| | Patients | 1 | 2019 | 169 | 0.140 |
Why?
| | Yoga | 1 | 2018 | 31 | 0.140 |
Why?
| | Community-Acquired Infections | 1 | 2019 | 160 | 0.140 |
Why?
| | Prurigo | 1 | 2016 | 2 | 0.130 |
Why?
| | Estrogen Replacement Therapy | 1 | 2018 | 137 | 0.130 |
Why?
| | Blood Glucose | 2 | 2024 | 2100 | 0.130 |
Why?
| | Regression Analysis | 1 | 2019 | 997 | 0.130 |
Why?
| | Sulfonylurea Compounds | 1 | 2017 | 46 | 0.130 |
Why?
| | Recurrence | 1 | 2020 | 1011 | 0.130 |
Why?
| | Nonprescription Drugs | 1 | 2017 | 66 | 0.130 |
Why?
| | Gastroesophageal Reflux | 1 | 2019 | 232 | 0.130 |
Why?
| | Smoking | 1 | 2024 | 1500 | 0.130 |
Why?
| | Dietary Supplements | 1 | 2020 | 534 | 0.130 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2017 | 46 | 0.130 |
Why?
| | Sleep | 1 | 2022 | 687 | 0.130 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 430 | 0.130 |
Why?
| | Pain | 2 | 2023 | 787 | 0.130 |
Why?
| | Exanthema | 1 | 2016 | 74 | 0.130 |
Why?
| | Psychiatry | 1 | 2018 | 179 | 0.120 |
Why?
| | Prednisone | 1 | 2016 | 234 | 0.120 |
Why?
| | Hemorrhage | 1 | 2020 | 680 | 0.120 |
Why?
| | Administration, Oral | 1 | 2018 | 787 | 0.120 |
Why?
| | Injections | 1 | 2016 | 174 | 0.120 |
Why?
| | Burnout, Professional | 2 | 2019 | 405 | 0.120 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2019 | 443 | 0.120 |
Why?
| | Diabetic Foot | 1 | 2015 | 25 | 0.120 |
Why?
| | Acute Disease | 1 | 2018 | 979 | 0.120 |
Why?
| | Health Status | 1 | 2020 | 756 | 0.120 |
Why?
| | Achilles Tendon | 1 | 2015 | 33 | 0.120 |
Why?
| | Quality of Health Care | 1 | 2019 | 604 | 0.110 |
Why?
| | Hospitalization | 1 | 2024 | 2057 | 0.110 |
Why?
| | Pandemics | 1 | 2022 | 1491 | 0.110 |
Why?
| | Tendon Injuries | 1 | 2015 | 69 | 0.110 |
Why?
| | Sulfonamides | 1 | 2018 | 497 | 0.110 |
Why?
| | Treatment Failure | 1 | 2015 | 339 | 0.110 |
Why?
| | Double-Blind Method | 1 | 2018 | 1875 | 0.110 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 1042 | 0.110 |
Why?
| | Young Adult | 2 | 2023 | 12455 | 0.110 |
Why?
| | Gestational Age | 1 | 2017 | 876 | 0.110 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 287 | 0.100 |
Why?
| | Osteomyelitis | 1 | 2015 | 121 | 0.100 |
Why?
| | Administration, Inhalation | 1 | 2015 | 667 | 0.100 |
Why?
| | Psychometrics | 1 | 2017 | 696 | 0.100 |
Why?
| | Skin Neoplasms | 1 | 2020 | 829 | 0.100 |
Why?
| | Colorado | 2 | 2019 | 4404 | 0.090 |
Why?
| | Alphapapillomavirus | 1 | 2010 | 39 | 0.090 |
Why?
| | Mental Disorders | 1 | 2018 | 1034 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 1914 | 0.070 |
Why?
| | Prospective Studies | 1 | 2018 | 7135 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 5415 | 0.060 |
Why?
| | Diagnostic Imaging | 1 | 2006 | 325 | 0.050 |
Why?
| | Adolescent | 1 | 2023 | 20412 | 0.050 |
Why?
| | Amitriptyline | 1 | 2023 | 20 | 0.050 |
Why?
| | Trigger Points | 1 | 2023 | 14 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2015 | 3394 | 0.050 |
Why?
| | Blood Pressure | 2 | 2022 | 1736 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1432 | 0.050 |
Why?
| | Dermoscopy | 1 | 2020 | 10 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2005 | 1005 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2022 | 485 | 0.040 |
Why?
| | Models, Organizational | 1 | 2019 | 145 | 0.040 |
Why?
| | Long-Term Care | 1 | 2019 | 92 | 0.040 |
Why?
| | Interdisciplinary Communication | 1 | 2018 | 184 | 0.030 |
Why?
| | Workflow | 1 | 2018 | 156 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1269 | 0.030 |
Why?
| | Skin | 1 | 2020 | 727 | 0.030 |
Why?
| | Blood Sedimentation | 1 | 2015 | 34 | 0.030 |
Why?
| | Rupture | 1 | 2015 | 92 | 0.030 |
Why?
| | Child | 2 | 2022 | 20884 | 0.030 |
Why?
| | Foot | 1 | 2015 | 93 | 0.030 |
Why?
| | Mental Health Services | 1 | 2018 | 404 | 0.030 |
Why?
| | Comorbidity | 1 | 2018 | 1547 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 569 | 0.030 |
Why?
| | Radiography | 1 | 2015 | 797 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2564 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 3774 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1843 | 0.020 |
Why?
| | Quality Improvement | 1 | 2018 | 1101 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 3262 | 0.020 |
Why?
| | Infant | 1 | 2022 | 8995 | 0.020 |
Why?
| | Risk Factors | 1 | 2017 | 9786 | 0.010 |
Why?
|
|
Lyon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|